Skip to main content
DNA logo

DNA · Ginkgo Bioworks Holdings, Inc.

Track DNA — free
$8.41 -1.20 (-12.49%)
Market Cap
$622.97M
Shares
64.83M
Volume · Nov 16 1.47M Avg daily vol (3M) 2.41M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$9.61 Open$10.00 Day$9.39–10.05 52W close$5.48–14.98 Avg vol 30d3.2M Short int9.5M · 14.6% of shares · 3.9d Short vol46% Last earningsNov 5, 2026 DataApr 2021–Nov 2026 Filing10-Q · Nov 9

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Biosecurity divestiture completed as revenue fell

Ginkgo Bioworks Holdings, Inc. completed the divestiture of its Biosecurity business on April 3, 2026, receiving minority equity in the purchaser. Nine-month revenue fell to $67.3 million, while continuing-operations net loss narrowed to $174.4 million.

Revenue $27.71M ▼ 5.7% Net loss $40.98M
Read from the MD&A section
4 source passages
On April 3, 2026, the Company completed a divestiture of its Biosecurity business, which was previously reported as a separate segment, whereby the Purchaser issued to the Company shares of common equity of the Purchaser representing a minority interest in the Purchaser in exchange for substantially all of the Company’s operations comprising its Biosecurity business We define EBITDA as net loss from continuing operations attributable to Ginkgo Bioworks Holdings, Inc. stockholders before the impact of interest income, interest expense, provision for income taxes and depreciation and amortization. Revenue was $67.3 million for the nine months ended September 30, 2026, compared to $106.7 million for the nine months ended September 30, 2025, a decrease of $39.4 million. Net cash used in operating activities for the nine months ended September 30, 2026 consisted of a net loss from continuing operations of $174.4 million, adjusted for net change in operating assets and liabilities of $42.3 million and non-cash charges of $99.7 million. Open the document at this passage
Nov 5
Earnings call
First pharma autonomous lab sale drives traction

Ginkgo won its first pharma autonomous lab sale with Novo Nordis in the third quarter of 2026. It held $285 million in cash and marketable securities, no bank debt, and reaffirmed cash burn guidance of 125 to 150 million dollars.

4 source passages
Novo Nordis selected Ginkgo to build an autonomous lab at their new R&D site in Waltham. Revenue was $28 million in the third quarter of 2026, down 6% compared to the third quarter of 2025. We ended the quarter with $285 million in cash, cash equivalents, and marketable securities, and no bank debt. In terms of the outlook for the full year, we are reaffirming our overall cash burn guidance for 2026 totaling 125 to 150 million dollars. Open the document at this passage
Nov 5
Current report 8-K
First autonomous lab sale signed with Novo

Ginkgo Bioworks signed its first autonomous lab sale to Novo and reported third quarter 2026 revenue of $28 million, a ($41) million GAAP net loss from continuing operations, ($22) million adjusted EBITDA, and $285 million in cash and marketable securities.

Financial results
5 source passages
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo Third quarter 2026 Revenue of $28 million compared to $29 million in the comparable prior year period, a decrease of 6%. Revenue increased from $20 million in the second quarter of 2026. Third quarter 2026 GAAP net loss from continuing operations of ($41) million, compared to ($73) million in the comparable prior year period. Third quarter 2026 Adjusted EBITDA of ($22) million, improved from ($53) million in the comparable prior year period. Cash, cash equivalents and marketable securities balance as of September 30, 2026 of $285 million. Open the document at this passage
Oct 29
Current report 8-K
Regulation FD disclosure

Ginkgo Bioworks will host a presentation and Q&A session on its third-quarter business performance on Thursday, November 5, 2026, beginning at 4:30 p.m. ET, reviewing the quarter ended September 30, 2026.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$130.75M
Trailing 12 months
Net income (TTM)
−$251.03M
Trailing 12 months
Revenue growth YoY
-5.7%
Year over year
Operating margin
-204.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-27.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$84.50M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.5%
Year over year · more shares
Price change (1Y)
+20.1%
Trailing year
Short interest
14.6%
Latest settlement · 3.9 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Ginkgo reported declining revenue and remained loss-making, but improved its net loss and ended with $285 million of cash and no bank debt. Business momentum included a Novo autonomous lab sale, an ARPA-H subcontract worth up to $17.5 million, university commissions, and 22 ADME customers signed in Q3, although management did not guide revenue and system installations typically take six to 12 months.

Bullish
  • + Signed an autonomous lab sale to a top-tier pharma company, Novo. new
  • + Won an ARPA-H subcontract worth up to $17.5 million for RNA-medicine manufacturing. new
  • + Continued expansion through NSF-backed university commissions and MIT Media Lab's RAC-based cloud lab. new
  • + Cloud Lab grew with 22 ADME customers signed in Q3, including 20 first-time Ginkgo customers. new
  • + GAAP net loss from continuing operations improved to $41 million from $73 million year over year. new
  • + Ended the quarter with $285 million in cash and no bank debt. new
Bearish
  • − Third-quarter revenue declined 6% year over year to $28 million.
  • − Nine-month revenue declined 37% year over year to $67 million.
  • − Adjusted EBITDA remained negative at $22 million, despite improving from negative $53 million. new
  • − Adjusted EBITDA continued to absorb approximately $14 million of excess-lease carrying costs. new
  • − Management did not provide revenue guidance or 2027 guidance. new
  • − Autonomous lab sales typically face a six-to-12-month installation timeline. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +11%
above
Price vs 50-day avg −7%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 43%
mid-range
Momentum
relative strength
Strong
1-month return −6%
trailing
6-month return +11%
trailing
YTD return +16%
this year
Relative strength +10%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow Accumulating
153 of 188 funds reported for Sep 30 · net +2.5M sh shares · +16 new
Insider flow Distributing
Net -$962.5K over 90 days · 100% sells
Short interest Rising
14.64% of shares out · ▲ +14.4% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
188 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Fair
Revenue growth −25%
Y/Y
EPS growth +46%
Y/Y
Free cash flow $-178.7M
Balance sheet $167.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 104%
annualized · 1-yr
Max drawdown −49%
past year
ATR 14.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the 8-K filed Nov 5, 2026
Total cash burn · 2026 Non-GAAP Maintained $-150M – $-125M
Aug 5, 2026 $-150M – $-125M changed to Nov 5, 2026 $-150M – $-125M
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Cash burn · full year 2026 $125M – $150M
Guided vs delivered · last 4 settled
Total revenue full year 2025
guided $167M – $187M
$170.16M In line
Total revenue 2024
guided $170M – $190M
$227.04M Beat +26.1%
Total revenue in 2023
guided $250M – $260M
$251.46M In line
Total revenue in 2022
guided $460M – $480M
$477.71M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+11% Bullish
Price vs 50-day avg
−7% Bearish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
43% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow Accumulating
153 of 188 funds reported for Sep 30 · net +2.5M sh shares · +16 new
Insider flow Distributing
Net -$962.5K over 90 days · 100% sells
Short interest Rising
14.64% of shares out · ▲ +14.4% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
188 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5 Now $10 · 43% Range high $15
vs 200-day avg +11% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP -78.54M Six Months Ended June 30, 2026 —
EBITDA non-GAAP -115.05M Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DNA
Ginkgo Bioworks Holdings, Inc.
this stock
$622.97M +15.6% -25.1% — 14.6%
VRTX
Vertex Pharmaceuticals Inc
$136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
$66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
180
% held
59.7%
Reported
153 of 188
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
143
View
Short & Settlement
Short Interest Rising
Shares short
9.5M
Days to cover
3.9d
Change
+1.2M sh
View
Short Volume
Short vol %
46%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.9K
Value
$20.0K
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
42.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$962.5K
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$170.2M
Net income (FY)
$-312.8M
EPS diluted
$-5.64
View
Buybacks
Remaining
shares 0
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 9, 2026
This year
17

Ginkgo Bioworks Holdings, Inc. completed the divestiture of its Biosecurity business on April 3, 2026, receiving minority equity in the purchaser. Nine-month revenue fell to $67.3 million, while continuing-operations net loss narrowed to $174.4 million.

View
Proposed Sales
Value
$7.8K
Shares
766
Filed
Oct 19, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Ginkgo Bioworks Reports Third Qua…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
DNA -14.9% -6.4% +10.6% -14.3% +15.6%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -17.5% -5.3% +10.1% -14.1% +5.0%

Capital returns

Buyback program · as of Dec 31, 2021
Authorized
—
Spent (derived)
—
Remaining
shares 0

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1830214 CUSIP 37611X209 13F (30d) 152 filings 116 filers Visit website Investor relations